Carolyn S P Lam, Lars H Lund, Sanjiv J Shah, Adriaan A Voors, David Erlinge, Antti Saraste, Carlo Pirazzi, Erik L Grove, Anders Barasa, Morten Schou, Ahmed Aziz, Sara Svedlund, Jan VAN Wijngaarden, Eva-Lotte Lindstedt, Andreas Gustavsson, Karin Nelander, Pavlo Garkaviy, Li-Ming Gan, Anders Gabrielsen
BACKGROUND: Inflammation is a key driver of heart failure (HF) with preserved left ventricular ejection fraction (LVEF). AZD4831 inhibits extracellular myeloperoxidase, reduces inflammation and improves microvascular function in preclinical disease models. METHODS: In this double-blind phase 2a study (SATELLITE; NCT03756285), patients with symptomatic HF, LVEF ≥40%, and elevated B-type natriuretic peptides were randomized 2:1 to once-daily oral AZD4831 5 mg or placebo for 90 days...
April 16, 2023: Journal of Cardiac Failure